Combined prophylactic and therapeutic immune responses against human papillomaviruses induced by a thioredoxin-based L2-E7 nanoparticle vaccine
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Combined prophylactic and therapeutic immune responses against human papillomaviruses induced by a thioredoxin-based L2-E7 nanoparticle vaccine
Authors
Keywords
T cells, Mouse models, HPV-16, Malignant tumors, Immune response, Antigens, Enzyme-linked immunoassays, Cytotoxic T cells
Journal
PLoS Pathogens
Volume 16, Issue 9, Pages e1008827
Publisher
Public Library of Science (PLoS)
Online
2020-09-05
DOI
10.1371/journal.ppat.1008827
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- The promise of combining cancer vaccine and checkpoint blockade for treating HPV-related cancer
- (2019) Takeo Shibata et al. CANCER TREATMENT REVIEWS
- The presence of human papillomavirus (HPV) in placenta and/or cord blood might result in Th2 polarization
- (2017) H.-M. Koskimaa et al. EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES
- Final efficacy, immunogenicity, and safety analyses of a nine-valent human papillomavirus vaccine in women aged 16–26 years: a randomised, double-blind trial
- (2017) Warner K Huh et al. LANCET
- Developments in L2-based human papillomavirus (HPV) vaccines
- (2017) Christina Schellenbacher et al. VIRUS RESEARCH
- Broadly neutralizing antiviral responses induced by a single-molecule HPV vaccine based on thermostable thioredoxin-L2 multiepitope nanoparticles
- (2017) Gloria Spagnoli et al. Scientific Reports
- Human papillomavirus type 16 viral load is decreased following a therapeutic vaccination
- (2016) Hannah N. Coleman et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- A first-in-human phase 1 trial to evaluate the safety and immunogenicity of the candidate tuberculosis vaccine MVA85A-IMX313, administered to BCG-vaccinated adults
- (2016) Alice Minhinnick et al. VACCINE
- A HIV-Tat/C4-binding protein chimera encoded by a DNA vaccine is highly immunogenic and contains acute EcoHIV infection in mice
- (2016) Khamis Tomusange et al. Scientific Reports
- Enhancing immunogenicity and transmission-blocking activity of malaria vaccines by fusing Pfs25 to IMX313 multimerization technology
- (2016) Yuanyuan Li et al. Scientific Reports
- Robust In Vitro and In Vivo Neutralization against Multiple High-Risk HPV Types Induced by a Thermostable Thioredoxin-L2 Vaccine
- (2015) H. Seitz et al. Cancer Prevention Research
- Unique potential of 4-1BB agonist antibody to promote durable regression of HPV+tumors when combined with an E6/E7 peptide vaccine
- (2015) Todd Bartkowiak et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- A phase I dose-escalation clinical trial of a peptide-based human papillomavirus therapeutic vaccine withCandidaskin test reagent as a novel vaccine adjuvant for treating women with biopsy-proven cervical intraepithelial neoplasia 2/3
- (2015) William W Greenfield et al. OncoImmunology
- Design, Immune Responses and Anti-Tumor Potential of an HPV16 E6E7 Multi-Epitope Vaccine
- (2015) Liliane Maria Fernandes de Oliveira et al. PLoS One
- A three component mix of thioredoxin-L2 antigens elicits broadly neutralizing responses against oncogenic human papillomaviruses
- (2014) Hanna Seitz et al. VACCINE
- A high-performance thioredoxin-based scaffold for peptide immunogen construction: proof-of-concept testing with a human papillomavirus epitope
- (2014) Elena Canali et al. Scientific Reports
- Influence of Oxidation and Multimerization on the Immunogenicity of a Thioredoxin-L2 Prophylactic Papillomavirus Vaccine
- (2013) Hanna Seitz et al. Clinical and Vaccine Immunology
- Clinical trials of human papillomavirus vaccines and beyond
- (2013) Matti Lehtinen et al. Nature Reviews Clinical Oncology
- High-Throughput Pseudovirion-Based Neutralization Assay for Analysis of Natural and Vaccine-Induced Antibodies against Human Papillomaviruses
- (2013) Peter Sehr et al. PLoS One
- Next-generation peptide vaccines for advanced cancer
- (2012) Akira Yamada et al. CANCER SCIENCE
- Fusion of the Mycobacterium tuberculosis Antigen 85A to an Oligomerization Domain Enhances Its Immunogenicity in Both Mice and Non-Human Primates
- (2012) Alexandra J. Spencer et al. PLoS One
- Preclinical development of highly effective and safe DNA vaccines directed against HPV 16 E6 and E7
- (2011) Koen Oosterhuis et al. INTERNATIONAL JOURNAL OF CANCER
- A Conserved E7-derived Cytotoxic T Lymphocyte Epitope Expressed on HumanPapillomavirus16-transformed HLA-A2+Epithelial Cancers
- (2010) Angelika B. Riemer et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Perspectives for Preventive and Therapeutic HPV Vaccines
- (2010) Ken Lin et al. JOURNAL OF THE FORMOSAN MEDICAL ASSOCIATION
- Potent anti-HPV immune responses induced by tandem repeats of the HPV16 L2 (20–38) peptide displayed on bacterial thioredoxin
- (2009) Ivonne Rubio et al. VACCINE
- Papillomaviruses in the causation of human cancers — a brief historical account
- (2009) Harald zur Hausen VIROLOGY
- The Oligomerization Domain of C4-Binding Protein (C4bp) Acts as an Adjuvant, and the Fusion Protein Comprised of the 19-Kilodalton Merozoite Surface Protein 1 Fused with the Murine C4bp Domain Protects Mice against Malaria
- (2008) S. A. Ogun et al. INFECTION AND IMMUNITY
- Generation and characterization of a preventive and therapeutic HPV DNA vaccine
- (2007) Daejin Kim et al. VACCINE
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started